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permeable small molecule reactivators of
protein phosphatase 2A in glioblastoma
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Patrik Johansson,3 William P. J. Leenders,5 David B. Kastrinsky,6,7 Nilesh Zaware,6
Goutham Narla,8 Pirjo Laakkonen,4,9 Sven Nelander,3 Michael Ohlmeyer6,10 and
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Glioblastoma is a fatal disease in which most targeted therapies have clinically failed. However, pharmacological reactivation of tu-
mour suppressors has not been thoroughly studied as yet as a glioblastoma therapeutic strategy. Tumour suppressor protein phos-
phatase 2A is inhibited by non-genetic mechanisms in glioblastoma, and thus, it would be potentially amendable for therapeutic re-
activation. Here, we demonstrate that small molecule activators of protein phosphatase 2A, NZ-8-061 and DBK-1154, effectively
cross the in vitro model of blood–brain barrier, and in vivo partition to mouse brain tissue after oral dosing. In vitro, small mol-
ecule activators of protein phosphatase 2A exhibit robust cell-killing activity against five established glioblastoma cell lines, and
nine patient-derived primary glioma cell lines. Collectively, these cell lines have heterogeneous genetic background, kinase inhibitor
resistance profile and stemness properties; and they represent different clinical glioblastoma subtypes. Moreover, small molecule
activators of protein phosphatase 2A were found to be superior to a range of kinase inhibitors in their capacity to kill patient-
derived primary glioma cells. Oral dosing of either of the small molecule activators of protein phosphatase 2A significantly reduced
growth of infiltrative intracranial glioblastoma tumours. DBK-1154, with both higher degree of brain/blood distribution, and
more potent in vitro activity against all tested glioblastoma cell lines, also significantly increased survival of mice bearing ortho-
topic glioblastoma xenografts. In summary, this report presents a proof-of-principle data for blood–brain barrier—permeable tu-
mour suppressor reactivation therapy for glioblastoma cells of heterogenous molecular background. These results also provide the
first indications that protein phosphatase 2A reactivation might be able to challenge the current paradigm in glioblastoma therapies
which has been strongly focused on targeting specific genetically altered cancer drivers with highly specific inhibitors. Based on
demonstrated role for protein phosphatase 2A inhibition in glioblastoma cell drug resistance, small molecule activators of protein
phosphatase 2A may prove to be beneficial in future glioblastoma combination therapies.
1 Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku 20520, Finland
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Introduction
One of the hallmarks of glioblastoma (GB) is dysregu-
lated phosphorylation-dependent pathways, which are
drivers of its malignant progression (Dunn et al., 2012).
Nevertheless, all tested kinase inhibitors have failed to
prolong the overall survival of GB patients in clinical tri-
als (Mooney et al., 2019; Tomiyama and Ichimura,
2019). One of the reasons is that the blood–brain barrier
(BBB) prevents the otherwise potentially effective kinase
inhibitors from reaching the brain at high enough con-
centrations (Harder et al., 2018). Another potential rea-
son is non-mutational plasticity induced by kinase
inhibitors in GB cells (van den Heuvel et al., 2017).
Notably, phosphorylation of GB driver pathways is not
only regulated by kinases, but also by phosphatases
(Narla et al., 2018; Tomiyama et al., 2019). Amongst
them, protein phosphatase 2A (PP2A) is a serine/threo-
nine phosphatase that regulates multiple oncogenic kinase
signalling pathways, as well as apoptotic mechanisms
(Perrotti and Neviani, 2013; Kauko and Westermarck,
2018). Interestingly, although PP2A is an established tu-
mour suppressor (Perrotti and Neviani, 2013; Narla
et al., 2018), the genes coding for PP2A complex compo-
nents are rarely mutated in clinical GB samples (Kaur
et al., 2016). Instead, GB cells overexpress endogenous
inhibitor proteins of PP2A (PAIPs)(Kauko and
Westermarck, 2018), such as PME-1, CIP2A and
ARPP19 (Jiang et al., 2016; Kaur et al., 2016; Qin et al.,
2018). Inhibition of these PP2A inhibitor proteins
restricts GB cell growth, and PME-1-mediated PP2A in-
hibition drives widespread kinase inhibitor resistance in
GB (Kaur et al., 2016). Because PP2A is non-genetically
inactivated in GB by the PAIPs, it could be a suitable tar-
get for tumour suppressor reactivation therapies
(Westermarck, 2018; Tomiyama et al., 2019).
A series of small molecule activators of PP2A
(SMAPs) were recently derived from tricyclic neurologic-
al drugs such as Chlorpromazine and Clomipramine
(Kastrinsky et al., 2015), which have a long association
with anti-proliferative properties in vitro (Sachlos et al.,
2012; Sangodkar et al., 2012), and with anti-cancer
effects in patients, based on epidemiology studies
(Dalton et al., 2006; Zingone et al., 2017). However, al-
though these drugs obviously cross BBB, attempts to
therapeutically exploit the anti-glioma properties of these
tricyclics themselves have failed due to their potent in-
herent effects on G protein-coupled receptor and amine
transporter pharmacology. Both activities are responsible
for central nervous system (CNS)—and cardiovascular
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toxicity when used at doses where anti-tumour effects
are manifest (Murren et al., 1996; Jahchan et al., 2013).
Based on photoaffinity labelling studies, radiolytic foot-
printing and mutagenesis of the binding site, the target
of SMAPs has been identified as the interface of the A
and C subunits in the PP2A complex (Sangodkar et al.,
2017). The SMAPs have shown efficacy as orally
available monotherapy in animal models in solid non-
CNS cancer types (Sangodkar et al., 2017; Kauko
et al., 2018), but neither their BBB penetration proper-
ties, nor potential as CNS cancer drug has not been
studied as yet.
Materials and methods
Compounds and cell lines
The synthesis of SMAPs is described in detail in public
patent application PCT/US2015/019674. For in vitro
work NZ-8-061 and DBK-1154 were dissolved in DMSO
and for in vivo work compounds were formulated in
10% N,N-dimethylacetamide (DMA—Sigma, cat#
27012), 10% Kolliphor HS 15 (solutol—Sigma, cat#
42966) and 80% sterile water, and kept in room tem-
perature and protected from light.
Established human GB cell lines U87MG, A172,
U118, E98-FM-Cherry (Claes et al., 2008) were cul-
tured in DMEM (Sigma-Aldrich) whereas T98G was
cultured in Eagle MEM (Sigma-Aldrich). Human fibro-
blasts (kind gift of Johanna Ivaska, Turku Bioscience,
Turku, Finland) were cultured in DMEM (Sigma-
Aldrich). All growth mediums were supplemented with
10% heat-inactivated foetal bovine serum (Biowest)
and fibroblasts medium was additionally supplemented
with 20% foetal bovine serum, 2 mmol/l L-glutamine
and penicillin (50 units/ml)/streptomycin (50 mg/ml).
Cultured were maintained in a humified atmosphere of
5% CO2 at 37
C.
Patient-derived glioma stem cell cultures were obtained
from HGCC biobank (Xie et al., 2015). BT3CD133þ
gliospheres were originated from surgical samples
(Kuopio University Hospital, Finland) during years 2010–
11 and sorted for their CD133 expression from BT3 cells
as described in Le Joncour et al. (2019a). Cells were cul-
tivated as adherent cultures in serum-free neural stem cell
(NSC) media containing an equal mix of DMEM/F12
(1:1) with glutamax (31331-093, Fisher Scientific) and
neurobasal (21103-049, Fisher Scientific) media with 1X
B-27 (12587001, Fisher Scientific) 1 N-2 (17502001,
Fisher Scientific) supplements, 1% penicillin-streptomycin
(P4333, Sigma-Aldrich), bFGF (10 ng/ml, 100-18B,
Peprotech) and EGF (10 ng/ml, AF-100-15, Peprotech)
(NSCþ/þ medium). Cells were cultured on Primaria ves-
sels (Fisher Scientific) coated with 1% laminin (L2020-
1MG, Sigma-Aldrich) solution in sterile PBS at 37C with
5% CO2.
Colony formation assay
Optimized number of cells (3  103 to 10  103) were
seeded in 12-well plates (Sigma-Aldrich) and allowed to
attach. After 24 h, cells were treated with determined
concentration of chemical compounds. After 72 h, me-
dium was replaced with non-drug containing medium
and the cells were left for another 72 h or until the con-
trol well was confluent. Cell colonies were fixed with ice-
cold methanol and stained with 0.2% crystal violet solu-
tion in 10% ethanol for 15 min at room temperature.
Plates were dried and scanned with Epson Perfection
V700 Photo scanner. Quantifications were performed
with ImageJ by using Colony area (Guzman et al., 2014)
plugin. Data were normalized and presented as a per
cent of the control.
Cell viability assay
Optimized number of U87MG, A172, U118, T98G and
E98 cells (3  103 to 5  103) were seeded in white 96-
well plates (Perkin Elmer) and allowed to attach. After
24 h, cells were treated with determined concentration of
chemical compounds for 24–72 h. Cell viability was
measured using a CellTitre Glo assay (Promega) accord-
ing the manufacturer’s instructions. Luminescence was
read with BioTek Synergy H1 plate reader (BioTek,
Country). Bioluminescence was normalized and presented
as a per cent of the control.
Cell viability for glioma stem cells was seeded into 96-
well plates 5  103 cells/well and allowed to attach over-
night. Next day medium was changed into a medium
containing drugs. After 72 h of treatment medium was
changed into fresh NSCþ/þ containing 10% of Alamar
blue solution (10099022, Fisher Scientific). Fluorescent
signal was measured after 210 min of incubation in 37C
using Wallac Victor 1420 plate reader (Perkin Elmer).
Fluorescence was normalized and presented as a per cent
of the control.
Animal experiments
The animal experiments for this study were carried out
according to the Animal Experiment Board in Finland
(ELLA) for the care and use of animals under the
licenses 4161/04.10.07/2015 and 9241/2018. Six- to 8-
week-old female athymic BALB/cOlaHsd-Foxn1nu
(Envigo, France). The animals were kept under specific
pathogen-free conditions in individually ventilated
cages in the animal care facility. Mice were kept on a
12-h light/dark cycle with access to the autoclaved water
and irradiated chow ad libitum. Mice were allowed to
adapt to the facility for 1 week before starting the
experiments.
The intracranial E98 GB mouse model was done by
preparing a cell suspension of 1.5  105 cells in 5 ml of
PBS which was inoculated into the brain of anaesthetized
(isoflurane) mice. Injection was done as followed. A small
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incision (0.5 mm) was made to skin middle of the skull
and a small hole (Ø 0.2 mm) was drilled above the injec-
tion site. Coordinates for the injection site from bregma:
1 mm posterior, 2 mm to right, 3 mm depth from the
skull. Injection was done slowly within 5 min and the
needle was allowed to stay in the brain for 5 min after
the injection. After the injection, wound was sutured and
mice were allowed to wake up in controlled environment.
After 10 days, mice were imaged with bioluminescence
and based on the bioluminescence signal from the tumour
the mice were randomized to two equal groups, control
and treated. Randomization was done with web-based
programme (Laajala et al., 2016). Drug treatment of the
mice was started after the randomization. The NZ-8-061
experiment had 8 mice per group and the DBK-1154 had
10 mice per group. NZ-8-061 and DBK-1154 were for-
mulated in 10% N,N-dimethylacetamide (DMA—Sigma,
cat# 27012), 10% Kolliphor HS 15 (solutol—Sigma, cat#
42966), 80% sterile water. In the studies, NZ-8-061 was
given 30 mg/kg and DBK-1154 100 mg/kg and dosed
twice a day. Higher dose for DBK-1154 is explained be-
cause of its lower bioavailability through oral dosing.
In the experiment’s tumour growth was monitored ap-
proximately twice a week by bioluminescence imaging
using Xenogen IVIS Spectrum (Caliper Life Sciences) until
the end of the experiment. For imaging, mice were
injected with 150 mg/kg mouse weight XenoLight D-luci-
ferin substrate (Caliper Life Sciences). The imaging was
performed under isoflurane gas anaesthesia. Images were
quantified with Living imageV
R
.
In the experiments, animals were monitored closely and
upon showing discomfort or weight loss (15%), they
were sacrificed, and their brains were harvested euthan-
ized by cervical dislocation. Brains were then removed
and either fixed in formalin or frozen in isopentane on
dry ice. Formalin-fixed samples were embedded in paraf-
fin, sectioned and histological or immunohistochemical
staining were performed with HE (Fluka, 03971),
Vimentin (Dako, M0725), Ki67 (Dako, M7240). Ki67
stainings were quantified with ImmunoRatio programme
(jvsmicroscope.uta.fi/immunoratio/).
Statistical analysis
The significance level of differences between the mean
values of two groups of data was evaluated as follows.
For in vivo bioluminescence follow-up, in vitro BBB dif-
fusion model, cell viability comparison and caspase 3/7
comparison a two-tailed unpaired Student’s t-test assum-
ing unequal variances among the sample means was
used. Ki67 comparison was determined with a two-tailed
Mann–Whitney test. Survival was determined by Gehan–
Breslow–Wilcoxon test. Differences with probability value
P< 0.05 were described as statistically significant.
Additional information is provided in Supplementary
methods.
Results
Development of BBB permeable
small molecule reactivators of
PP2A
We sought to improve the potency and oral bioavailabil-
ity of RTC-5 and RTC-30 (Kastrinsky et al., 2015), ear-
lier members of the SMAP series derived from tricyclics,
by constraint of the linear spacer moiety between the tri-
cyclic and sulfonamide, resulting in structures exemplified
by DBK-1154 and NZ-8-061 (Fig. 1A and
Supplementary Fig. 1). However, it was unclear whether
the polarity introduced to tricyclics by the sulfonamide
and hydroxyl moieties (Fig. 1A) would compromise BBB
permeability, and eventually CNS availability, of the
SMAPs as compared with tricyclics. We, therefore, started
by investigating the in vitro BBB passage of NZ-8-061
(a.k.a DT-061) that has been widely used in cancers out-
side the CNS (Sangodkar et al., 2017; Kauko et al.,
2018; McClinch et al., 2018). Quantified by HPLC-MS/
MS, NZ-8-061 was found to cross the artificial BBB (Le
Joncour et al., 2019b), consisting of murine brain micro-
capillary endothelial cells and astrocytes (Fig. 1B and C).
Furthermore, 24-h pre-treatment with NZ-8-061 did not
modify diffusion of a low-molecular weight fluorescent
probe, the sodium fluorescein (Na-Fl), indicating that pas-
sage of NZ-8-061 was not a bystander effect due to its
effects on BBB model permeability (Fig. 1D).
To study brain penetration of NZ-8-061 in vivo, we
performed a pharmacokinetic study by either administer-
ing 1 mg/kg i.v. or a bolus oral dose of 100 mg/kg. The
in vivo pharmacokinetic parameters are shown in
Fig. 1E. NZ-8-061 shows 100% oral bioavailabilty based
on dose-adjusted fraction absorbed (%F) and moderate
clearance as judged from half-life (T1/2) in plasma with
T1/2 of 3 h after I.V. dose. Peak plasma concentration
after oral dose is around 14 mM and combined with
moderate clearance and high area under curve, shows sig-
nificant, and sustained systemic exposure. Importantly,
based on HPLC-MS/MS analysis from the whole-brain
homogenate, NZ-8-061 partitions into brain with a
brain/plasma ratio of 1:1 at 6 h post-drug administration
(Fig. 1E).
Together these results identify NZ-8-061 as an orally
bioavailable, and BBB-permeable drug candidate for GB
treatment.
NZ-8-061 potently inhibits the
viability of GB cells with
heterogenous genetic background
Frequency of genetic mutations or deletions in any of the
genes coding for core PP2A complex components in GB
clinical isolates is negligible (Kaur et al., 2016). However,
we found that all studied GB cell lines expressed higher
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levels of PP2A inhibitor proteins (PAIPs); PME-1, CIP2A,
SET and ARPP-19 (Kauko and Westermarck, 2018), as
compared with non-tumour fibroblasts (Fig. 2A). These
results provide a non-genetic candidate mechanism for
PP2A deregulation in GB cells.
Genomic heterogeneity and stemness characteristics are
known to affect GB cell therapy responses. Genomic
characteristics of the U87MG, A172, U118 and T98G
cell lines were examined using the Cancer Cell Line
Encyclopedia (CCLE) (Barretina et al., 2012) database,
whereas for the E98 cells published data were used
(Claes et al., 2008; Navis et al., 2015). Collectively, the
cell lines displayed a variety of known genomic altera-
tions in GB (Supplementary Fig. 2A). However, the only
common genomic change across all cell lines was copy
number loss of CDKN2A (Supplementary Fig. 2A).
Related to stemness properties, most of the established
cell lines, except for E98, did not express glioma stem
cell markers SOX2 or Nestin (Fig. 2B).
We previously demonstrated notable kinase inhibitor
resistance of T98G cells across different kinase families
(Kaur et al., 2016). To further examine kinase inhibitor
responses of the used cell lines, we extracted the IC50
values for selected inhibitors from Genomics of Drug
Sensitivity in Cancer database (https://www.cancerrxgene.
org/). No information for E98 cell line was available.
Consistently with their heterogenous mutation profiles
(Supplementary Fig. 2A), each of the cell line has very
variable sensitivity against different kinase inhibitors
(Supplementary Fig. 2B). We experimentally validated
Gefitinib resistance of three of the cell lines
(Supplementary Fig. 2C).
Figure 1 BBB penetrance and mouse in vivo pharmacokinetics of NZ-8-061. (A) An overview of development of SMAPs, NZ-8-061
and DBK-1154. The synthesis is described in detail in Supplementary Fig. 1. (B) Schematic presentation of in vitro BBB model, which consists of
murine endothelial cells and astrocytes. (C) NZ-8-061 passage through the in vitro BBB model after addition of 15 mM dosage on the upper
chamber at indicated timepoints. Data shown are means from two replicates 6 SD. (D) Sodium-fluorescein diffusion through the in vitro BBB
after 24 hour of pre-treatment with 15 mM NZ-8-061 on the upper chamber. Fluorescence signal of sodium fluorescein was measured from
lower chamber after 15 min. Data shown are means from two replicates 6 SD. (E) Mouse in vivo pharmacokinetic parameters (T1=2 h, Tmax h,
Cmax ng/ml, area under curve hr.ng/ml, CL ml/h/kg, %F and blood–brain ratio) after 1 or 100 mg/kg dosage via p.o. or i.v. of NZ-8-061.
PP2A reactivation therapy for glioblastoma BRAIN COMMUNICATIONS 2020: Page 5 of 12 | 5
D
ow
nloaded from
 https://academ
ic.oup.com
/braincom
m
s/article/2/1/fcaa002/5700713 by N
ational Library of H
ealth Sciences user on 26 O
ctober 2020
These genetically diverse cell lines, displaying differen-
tial drug sensitivities, were then screened for their re-
sponse to PP2A reactivation by NZ-8-061 in a cell
viability assay. NZ-8-061 did induce a dose-dependent re-
duction in cell viability in all of the tested cell lines
(Fig. 2C). Opposite to their kinase inhibitor responses,
neither drastic differences nor correlations of response
with their genetic background, were found among the
tested cell lines based on their IC50s. As a pharmacologic
control, U87MG, U118 or A172 cells were also treated
with increasing doses of TRC-766, a structurally similar
but biologically inactive derivate of SMAPs
(Supplementary Fig. 3A) (Sangodkar et al., 2017;
McClinch et al., 2018). While TRC-766 still binds PP2A,
Figure 2 NZ-8-061 potently inhibits viability of molecularly heterogenous GB cells in vitro. (A) Western blot of endogenous PP2A
inhibitor proteins (CIP2A, SET, PME-1 and ARPP-19) and (B) GB stem cell markers (Sox2 and Nestin) in indicated GB cell lines. BT3-CD133þ
(BT3 patient-derived cells sorted for CD133) cells were used as a control for GB stem cell markers, and human fibroblasts were used as a
negative control cell line in both. Please see Supplementary material of full uncut western blots. (C) The dose-dependent effect of NZ-8-061 on
the viability of indicated GB cell lines after 72 h. Data shown are means from six replicates 6 SD. IC50 values were calculated with GraphPad
Prism 8. (D, E) Colony growth inhibition after NZ-8-061 treatment in GB cell lines with indicated concentrations. IC50 values for each cell line
are shown. Data shown are means from four replicates 6 SD. IC50 values were calculated with GraphPad Prism 8. (F) Expression levels
endogenous PP2A inhibitor proteins (CIP2A, SET, PME-1 and ARPP-19) in patient-derived primary glioma cells. Please see Supplementary
material for full uncut western blots. (G) Cell viability inhibition after NZ-8-061 (5 mM) treatment in patient-derived primary glioma cells. Data
shown are means from six replicates 6 SD.
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it is unable to reactivate PP2A even at a concentration of
20 mM in vitro (Sangodkar et al., 2017). Notably, TRC-
766 did not affect the viability of GB cells at concentra-
tions up to 40 mM (Supplementary Fig. 3B). This strongly
supports a dependence on PP2A reactivation for NZ-8-
061-elicited killing of GB cells. Using a colony growth
assay, NZ-8-061 treatment resulted in dose-dependent
growth inhibition in all of the cell lines tested and in ap-
proximately the same concentration range as seen in the
cell viability assay (Fig. 2D and E). Of note, micromolar
dosing of SMAP is consistent with micromolar concentra-
tion of its molecular target PP2A in cancer cells, and
required as serum binding of these compounds decreases
their apparent potency in standard cell culture medium.
To extend these observations, we tested the therapeutic
potential of NZ-8-061 in a series of thoroughly validated
patient-derived primary glioma cells (Xie et al., 2015).
Notably, chosen cells represented all three molecular sub-
types of GB according to Verhaak and colleagues (Wang
et al., 2017) (Supplementary Fig. 4A and B). Each of the
patient-derived glioma cell line, cultured in serum-free
NSC media for the maintenance of stemness properties,
expressed Nestin and Sox2, as well as PAIPs
(Supplementary Fig. 4C and Fig. 2F). Furthermore, they
have a diverse genetic background (Supplementary Fig.
5A and B), and kinase inhibitor responses
(Supplementary Fig. 6). All nine tested primary glioma
cell lines displayed near to complete suppression of cell
viability when treated with 5 mM NZ-8-061 (Fig. 2G).
The lower working concentration of NZ-8-061 as com-
pared with standard GB cell line cultures could be
explained by the lack serum in the NSC media, thus
increasing the apparent potency of NZ-8-061.
Together these data demonstrate that SMAPs, as exem-
plified by NZ-8-061, have wide-spectrum therapeutic ef-
fect in vitro across human GB cells; regardless of their
genetic background, disease subtype or stemness
properties.
Preclinical activity of NZ-8-061 in
an infiltrative intracranial GB model
To analyse in vivo therapeutic potential of oral dosing of
NZ-8-061, we used an intracranial GB tumour model
with luciferase-expressing/bioluminescent E98 cells (Claes
et al., 2008). Among the cell lines, E98 cells were
selected as a model due to their aggressivity; i.e. stem-like
properties (Fig. 2B), and infiltrative growth pattern in
mouse brain recapitulating the human malignant glioma
histology (Claes et al., 2008) (Fig. 3A). E98 was thought
to be a representative cell line for assessing SMAP re-
sponse in vivo also due to their average to low NZ-8-
061 responsiveness in vitro (Fig. 2C and E). Prior to the
treatment, mice were randomized into two groups based
on the tumour bioluminescence signal and using a proto-
col for optimized design and analysis of preclinical inter-
vention studies in vivo (Laajala et al., 2016). NZ-8-061
was thereafter orally dosed twice a day at 30 mg/kg.
Based on pharmacokinetics and tissue distribution
(Fig. 1E), the brain exposure of NZ-8-061 was estimated
to transiently reach 10 mM, which is roughly comparable
to the IC50 for colony formation assay with NZ-8-061
in vitro (Fig. 2E).
Intracranial tumour growth was followed by biolumin-
escence measurements every third day. Notably, NZ-8-
061 induced tumour growth stasis at day 12 and dis-
played a significant reduction in tumour size at later
timepoints (Fig. 3B). The therapeutic response was vali-
dated by significant inhibition in tumour cell Ki67 ex-
pression in the endpoint tumours when comparing
treated and non-treated groups (Fig. 3C and D).
Importantly, analysis of contralateral brain hemisphere
without injected tumour cells from NZ-8-061 treated
mice, did not show after 21 days any apparent signs of
tissue toxicity based on H&E staining, or analysis of
apoptosis activity by TUNEL staining (Supplementary
Fig. 7). Consistent with previously published data
(Sangodkar et al., 2017; Kauko et al., 2018), NZ-8-061
treated mice did not also show any systemic signs of tox-
icity, or weight loss (Supplementary Fig. 8A).
DBK-1154, with higher degree of
brain/blood distribution, and more
efficient in vitro activity, increases
survival of mice bearing orthotopic
GB tumours
Despite its significant in vivo efficacy in reducing intra-
cranial tumour growth with roughly IC50 dosing
(Fig. 3B–D), NZ-8-061 monotherapy failed to improve
the mouse survival (Supplementary Fig. 8B). We, there-
fore, next tested the BBB permeability and GB cell-killing
properties of DBK-1154. DBK-1154, with a dibenzoaze-
pine tricyclic, has a hydrocarbon bridge versus an oxygen
bridge in NZ-8-061 (Fig. 1A), making DBK-1154 some-
what more lipophilic. The calculated LogP (log octanol-
water partition coefficient), a measure of lipophilicity, is
higher for DBK-1154 (cLogP 7.0) than NZ-8-061 (cLogP
6.6). In addition, total polar surface area is higher for
NZ-8-061 versus DBK-1154 (88 vs 79 A2). Lower total
polar surface area and higher cLogP generally correlate
with higher CNS distribution (Kelder et al., 1999).
In vivo pharmacokinetic parameters for DBK-1154
in mouse are shown in Fig. 4A and in Supplementary
Fig. 8C. DBK-1154 is orally bioavailable; however, it
showed significantly lower systemic plasma exposure
compared with NZ-8-061. Importantly, in addition to in
vitro BBB permeability (Supplementary Fig. 9A and B),
the in vivo evaluation of distribution of DBK-1154 into
the CNS showed a 2.3-fold higher concentration in brain
tissue versus plasma (Fig. 4A).
Based on the IC50-value, higher potential of DBK-
1154 was seen in addition to cell viability assay
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(Supplementary Fig. 9C), also in a long-term colony
growth assay in which the IC50 for DBK-1154 was al-
most 2-fold lower than that of NZ-8-061 in both cell lines
(Fig. 4D, insert). In addition, DBK-1154 was qualitatively
different from NZ-8-061 in terms of its apoptosis-inducing
potential. With single 13mM dosing, only DBK-1154
induced Caspase-3/7 cleavage at 48 h (Fig. 4B). This was
reflected in a significant time-dependent difference in inhib-
ition of cell viability also starting at 48 h (Fig. 4C). The
higher potency of DBK-1154, when compared with NZ-8-
061, was also seen across patient-derived primary glioma
cells in which DBK-1154 induced complete inhibition of
cell viability (Fig. 4E). Importantly, using the same cell cul-
ture conditions, most of the tested kinase inhibitors did
not reach even 50% reduction in cell viability with up to
10mM concentration in all five of the tested patient-
derived primary glioma cells (Supplementary Fig. 6).
Next, we proceeded to test DBK-1154 in the same
intracranial E98 model as with NZ-8-061. To compen-
sate for the lower oral bioavailability of DBK-1154, it
was dosed at 100 mg/kg, twice daily, using the same
homogeneous formulation, with expected transient brain
exposure of about 8 mM twice a day. This level of CNS
exposure is roughly comparable with the IC50 for colony
Figure 3 Therapeutic potential of oral dosing of NZ-8-061 as monotherapy in an infiltrative intracranial GB mouse model. (A)
Example picture of infiltrative growth of intracranial human E98-FM-Cherry cell line xenograft. The mouse brain tissue was stained with human-
specific vimentin antibody. (B) Bioluminescence follow-up of the intracranial human E98-FM-Cherry cell line xenograft growth during vehicle or
30 mg/kg NZ-8-061 treatment. When tumours were visible with bioluminescence, mice were randomized for either vehicle or NZ-8-061
groups. Data shown are means from eight mice 6 SEM, P-values by Student’s t-test. (C) Representative images of Ki-67 staining from four vehicle
and four NZ-8-061-treated endpoint tumours from B. (D) Quantification of Ki-67 positivity from C. Data shown are means of % of Ki-67
positive tumour cells from 7 to 8 tumours/group 6 SD, *P-value by Mann–Whitney test.
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formation for DBK-1154 in vitro (Fig. 4D). DBK-1154
therapy caused tumour growth reduction after day 5
(Supplementary Fig. 9D), and reaching statistically
significant difference at day 14 (Fig. 4F). Furthermore,
while NZ-8-061 monotherapy did not increase the
survival of the intracranial tumour-bearing mice
Figure 4 Oral dosing of DBK-1154 increases survival of mouse with intracranial infiltrative GB xenograft. (A) Mouse in vivo
pharmacokinetic parameters (T1=2 h, Tmax h, Cmax ng/ml, area under curve h.ng/ml, CL ml/h/kg, %F and blood–brain ratio) after 100 mg/kg dosage
via p.o. of DBK-1154. (B) Time-dependent Caspase-3/7 activation in E98 cells, after either DT-061 or DBK-1154 treatment (13 mM). Data shown
are means from six replicates 6 SD. (C) Time-dependent inhibition of cell viability in E98 cells, after either DT-061 or DBK-1154 treatment (13
mM). Data shown are means from six replicates 6 SD. (D) Colony growth reduction after DBK-1154 treatment in GB cell lines in indicated
concentrations. IC50 comparison between DBK-1154 and NZ-8-061 is shown in the insert. Data shown are means from four replicates 6 SD.
(E) Cell viability inhibition after DBK-1154 (5 mM) treatment in patient-derived primary glioma cells cultured in serum-free NSC medium. Data
shown are means from six replicates 6 SD. (F) Bioluminescence comparison on the day 14 during the orthotopic E98 in vivo model between
vehicle or 100 mg/kg DBK-1154 treatment. Data shown are means from 8 vehicle and 10 DBK-1154-treated mice 6 SEM, *P-value by Student’s
t-test. (G) Survival of mice with orthotopic E98 xenografts after vehicle or 100 mg/kg DBK-1154 treatment, *P < 0.05 by Gehan–Breslow–
Wilcoxon test. Mice were randomized to two groups of 10 mice each based on bioluminescence signal before starting the treatment. Median
survival was increased with DBK-1154 treatment from 15 to 26 days.
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(Supplementary Fig. 8B), the higher in vitro efficiency
and in vivo brain penetrance of DBK-1154 translated to
a significant, almost 2-fold longer overall mouse survival.
The median survival was 15 days for the control group,
and 26 days for the DBK-1154 treated group (P¼ 0.012)
(Fig. 4G). Together these data indicate that of the studied
SMAPs, DBK-1154 has a greater potential as a GB ther-
apy candidate molecule.
Considering the potential future development of DBK-
1154 derivatives for GB therapy, DBK-1154 was evaluated
in an acute rat pilot (non-good laboratory practice) toxicol-
ogy study at doses up to 800 mg/kg daily. Consistently
with previous SMAP in vivo studies (Sangodkar et al.,
2017; Kauko et al., 2018; McClinch et al., 2018), no sig-
nificant body weight loss, deaths or adverse behavioural or
neurological effects were observed. The major morphologic
finding was hepatocellular hypertrophy (panlobular) in all
test article-treated groups, with increased severity as the
dose level increased. This observation was likely related to
compound specific pregnane X receptor agonist activity,
and was considered an adaptive rather than toxic effect.
These findings indicate for a clear therapeutic window be-
tween normal and cancer cells in vivo.
Discussion
Collectively, these results provide proof-of-principle evi-
dence for preclinical in vivo efficacy, and acceptable
safety profile of SMAPs as novel candidate class of BBB
penetrable, tumour suppressor reactivation therapeutics.
Notably, the efficacy of SMAPs did not depend on the
subtype of GB, or the genomic alterations, in either
established GB cell lines or in patient-derived primary gli-
oma cells. Moreover, SMAPs were found to be superior
to a range of kinase inhibitors in their capacity to kill
patient-derived primary glioma cells. These results provide
the first indications that PP2A reactivation might be able
to challenge the current paradigm in GB therapies which
has been strongly focused on targeting specific genetically
altered cancer drivers with highly specific inhibitors
(Verhaak et al., 2010; Barretina et al., 2012; Brennan
et al., 2013). PP2A is known to simultaneously target a
number of cancer driver pathways and pro-apoptotic
mechanisms (Perrotti and Neviani, 2013; Kauko and
Westermarck, 2018). We envision that these wide-spec-
trum effects may explain the very robust preclinical sur-
vival effects across kinase inhibitor-resistant cell lines
harbouring heterogenous genetic drivers. The clear limita-
tion of the study was that the in vivo therapeutic efficacy
studies with SMAPs were limited to only one cell model;
highly invasive E98 cells (Fig. 3A) with stemness charac-
teristics (Fig. 2B). Therefore, therapeutic effects of SMAPs
need to be tested in the future by using cell models repre-
senting all major GB classes.
Another serious obstacle for development of GB thera-
pies is inadequate exposure of most developed molecules
in the CNS due to the BBB (Harder et al., 2018). Here,
we show that both SMAPs have retained the BBB pene-
tration properties of tricyclics from which they were
derived. This was not obvious as SMAPs are significantly
modified from the original tricyclics by replacement of a
tertiary amine salt with an aryl sulfonamide and addition
of a hydroxyl moiety. The observation that out of the
studied SMAPs, DBK-1154 preferably partitions into the
brain, is consistent with its lower total polar surface area
and higher cLopP. Consequently, this better brain parti-
tioning can partly explain the significant almost 2-fold
prolongation of survival of mice with DBK-1154 versus
NZ-8-061. In addition to GB, poor small molecule BBB
penetration is a serious problem also for the therapy of
brain metastasis from many non-CNS cancer types. As
these are more common than primary brain tumours
such as GB, the presented proof-of-principle data for use-
fulness of SMAPs as CNS therapeutics might be relevant
for much larger patient population than only GB
patients.
In addition to their different in vivo brain penetrance
properties, NZ-8-061 seems to have cytostatic effects at
the doses tested, whereas DBK-1154 most probably indu-
ces both, decreased proliferation and cell death. On the
other hand, a SMAP derivative DBK-766 defective in
PP2A reactivation (Sangodkar et al., 2017; McClinch
et al., 2018), failed to suppress GB cell viability as
expected. The intracellular pathways involved in the
apoptosis induction by DBK-1154 in vitro were not
addressed in this report, but clearly remains as an im-
portant future question to be addressed. As such, the
results provide a clear indication that chemical structure
of DBK-1154 could serve as a scaffold for further devel-
opment of even more potent SMAPs for GB therapy.
Following this rationale, a medicinal chemistry pro-
gramme identifying DBK-1154 analogues with improved
metabolic stability and oral bioavailability is currently in
progress.
PP2A activity is known to modulate kinase inhibitor
responses in haematological and solid cancers (Neviani
et al., 2013; Kaur et al., 2016; Kauko et al., 2018). In
vivo, combination studies with SMAPs demonstrated sig-
nificant tumour regression in KRAS-mutant lung cancer
xenograft model with MEK inhibitors (Kauko et al.,
2018). Therefore, the results reported here not only serve
as a proof-of-principle for the feasibility of SMAPs as
novel GB therapeutics, but also pave the way for future
combination studies with kinase inhibitors, and potential-
ly also other type of therapies in brain cancers.
Suppression of PP2A activity is also one of the pathogen-
ic mechanisms underlying several neurodegenerative dis-
eases, including Alzheimer’s (Shentu et al., 2018) and
Parkinson’s diseases; thus, our data demonstrating BBB
penetration and in vivo therapeutic effects of SMAPs in
the intracranial model described here may also prompt
the use of SMAPs in other CNS pathologies.
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